



## Corporate Profile

Message  
from the President

Philosophy

Corporate  
Profile

Corporate  
History

Business  
Units

Aiming  
Future

# Innovation today, healthier tomorrows

## The Slogan with our full commitment

The Slogan reflects full commitment to deliver to society innovative products and healthcare solutions, created through groundbreaking ideas and high-standard research and development by each individual employee's challenge for innovation, so as to help enable the patients and their families lead healthier and fulfilling lives. It also expresses our Mission symbolically.



# Message from the President



**Hiroshi Nomura**

Representative Director,  
President and CEO  
Sumitomo Pharma Co., Ltd.

My name is Hiroshi Nomura, and I have the honor of serving as Representative Director, President and CEO of Sumitomo Pharma Co., Ltd.

In October 2005, Sumitomo Pharmaceuticals Co., Ltd. and Dainippon Pharmaceutical Co., Ltd. merged under the trade name Sumitomo Dainippon Pharma Co., Ltd. During the 16 and a half years since the merger, we have undergone a major transformation. We have globalized our business, entered new research areas, and taken on numerous challenges such as large-scale acquisitions and partnerships. For us to grow continuously and evolve toward a new business stage, we have changed the name of the company from “Sumitomo Dainippon Pharma” to “Sumitomo Pharma,” and renewed our Group’s brand using the globally recognized “Sumitomo” brand, on April 1st, 2022.

Sumitomo Pharma Group operates every day to achieve its Mission “to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide.” By directing our efforts into the research and development of new drugs, we aim to provide innovative and valuable pharmaceutical and healthcare solutions to people not only in Japan but also around the world to realize our Mission.

With a focus on the Psychiatry & Neurology and Oncology disease areas, where unmet medical needs are high, the Sumitomo Pharma Group will make the utmost of the experience and knowledge that we have acquired so far to continue making active efforts for research and development of pharmaceuticals, regenerative medicine/cell therapy, non-pharmaceutical products, and otherwise. In other areas, too, we will tap into assets at hand and make steady R&D efforts to deliver solid value to patients. In addition, we are engaged in business activities with the goal of becoming the number one company in diabetes in Japan.

We will also engage in a wide range of other initiatives, including active dialog with diverse stakeholders such as patients, their families, healthcare professionals, our shareholders, other investors, employees, business partners, and the local communities in which we work; social contribution activities in and outside Japan; and promotion of diversity and inclusion. At the same time, by strengthening our corporate governance system and thoroughly ensuring compliance in the conduct of our business, we will continuously enhance our corporate value and thereby contribute to the creation of a more sustainable society.

All Sumitomo Pharma Group executives and employees to work together with a single purpose of doing our best work to earn and maintain the trust of our stakeholders and continue to be a company that delivers better health and well-being.

On behalf of all of us at Sumitomo Pharma, I would like to sincerely thank you for your ongoing support and encouragement.

# Philosophy

We share our Mission (the significance of the Group's existence, promises and missions to society,) Values (values that all executives and employees should share), and the Declaration of Conduct (the code of conduct to be observed in daily work) as our Philosophy throughout Sumitomo Pharma Group. We strive to enhance corporate value and contribute to solving social issues under the Sumitomo's Business Philosophy.

## Mission

To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide

## Values

- Patient First
- Always with Integrity
- One Diverse Team

## Declaration of Conduct

At Sumitomo Pharma Group and its subsidiaries (the "Group"), managements and employees aim to be companies that are trusted by society and have a strong presence through continuous business development. We are determined not only to comply with all laws and regulations, but also to ensure that all corporate activities are carried out in accordance with this Declaration of Conduct. The pledges below express our commitment to continuously contribute to improving corporate values and solving social issues.

Top managements of the Group recognize their roles to realize the spirit of this Declaration and take the lead in an exemplary manner to implement the Declaration within the corporation, while encouraging their business counterparts to follow the same example.

In the event the Declaration is violated, top managements should take charge to resolve the situation and make efforts to determine the cause of infringement and prevent similar violations in the future. At the same time, top managements should disclose information in a timely and appropriate manner, explain what has occurred, and, upon determining the source of competence and responsibility, impose strict disciplinary action against those responsible, including top managements themselves.

- 1. Follow through on our Slogan "Innovation today, healthier tomorrows."**
- 2. Pursue trustworthy corporate activities.**
- 3. Transparently disclose and properly manage information.**
- 4. Improve individual capabilities and collaborate with peers.**
- 5. Respect human rights.**
- 6. Positively address global environmental issues.**
- 7. Build harmonious relationships with society.**

## Brand Mark



*Igeta*, the Sumitomo trademark and the corporate symbol of Sumitomo Pharma Co., Ltd. is a common mark for the Sumitomo Group.

The corporate color of "SMP Green" represents on the hue of fresh young leaves and other images of healthy and energetic moods, and signs of what the future holds.

# Corporate Profile

Name	Sumitomo Pharma Co., Ltd.
Establishment	May 14, 1897
Capitalization	22.4 billion yen
Employees	3,026 (6,250 : consolidated) (as of March 31, 2023)
Key Facilities	〈Head Offices〉 Osaka Head Office, Tokyo Head Office 〈Branches〉 12 Branches 〈Plants〉 Suzuka Plant, Oita Plant 〈Research Laboratories〉 Central Research Laboratories, Osaka Research Center 〈Distribution Center〉 Kobe Distribution Center, Tokyo Distribution Center

Business (consolidated) Manufacturing and sales of pharmaceuticals and others


Osaka Head Office 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, 541-0045, Japan

Tokyo Head Office Tokyo Nihonbashi Tower, 2-7-1, Nihonbashi, Chuo-ku, Tokyo, 103-6012, Japan


Business Results (Year ended March 31, 2023)

Revenue (555.5 billion yen)  
Core operating profit (16.4 billion yen)  
R&D expenses (106.1 billion yen)

## Segment Revenue




# Corporate History



**Sumitomo Dainippon Pharma (currently, Sumitomo Pharma) created on October 1, 2005.**


- |             |  |
|-------------|--|
| <b>2009</b> | ● Acquired Sepracor Inc., a U.S. company (currently, Sumitomo Pharma America, Inc.).   |
| <b>2012</b> | ● Acquired Boston Biomedical, Inc., a U.S. company (currently, Sumitomo Pharma America, Inc.).<br>● Sunovion Pharmaceuticals Inc. acquired Elevation Pharmaceuticals, Inc., a U.S. company.  |
| <b>2013</b> | ● A subsidiary (currently, Sumitomo Pharma Asia Pacific Pte. Ltd.) established in Singapore.   |
| <b>2014</b> | ● Joint venture company (Sighregen Co., Ltd.) established.   |
| <b>2017</b> | ● Acquired Tolero Pharmaceuticals, Inc., a U.S. company (currently, Sumitomo Pharma America, Inc.).  |
| <b>2018</b> | ● Manufacturing Plant for Regenerative Medicine & Cell Therapy (SMaRT) completed.  |
| <b>2019</b> | ● Consolidation of production sites. (Reorganized four plants to two plants)<br>● With the signing of a strategic alliance agreement with Roivant Sciences, a U.S. subsidiary Sumitovant Biopharma was established to hold shares of Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences, and Spirovant Sciences. |
| <b>2020</b> | ● Joint venture company (S-RACMO Co., Ltd.) for CDMO Business in the field of Regenerative Medicine and Cell Therapy established.  |
| <b>2021</b> | ● Entered into an agreement for joint development and commercialization in Psychiatry and Neurology area with Otsuka Pharmaceutical Co., Ltd.  |
| <b>2022</b> | ● Changed company name from Sumitomo Dainippon Pharma Co., Ltd. to Sumitomo Pharma Co., Ltd.   |
| <b>2023</b> | ● Sumitomo Pharma Food & Chemical Co., Ltd. and Sumitomo Pharma Animal Health Co., Ltd. transferred.<br>● Mid-term Business Plan 2027 (FY2023-FY2027) drawn up.  |

## Trend of Business Results



## Business Units

We have a strong platform with head office, sales, and developing functions in Japan, North America, and China.



### Japan Business

In addition to the Psychiatry & Neurology area, we are focusing on Diabetes and Rare diseases areas.

#### Number of employees

Sumitomo Pharma Co., Ltd.: 3,026 (As of March 31, 2023)

#### Main Products

##### TRERIEF®

Revenue	16.7 billion yen (FY2022)
Launch	March 2009
Indications	Parkinson's disease, Parkinsonism in dementia with Lewy bodies
Features	Parkinson's disease drug with levodopa-enhancing effect



##### LATUDA®

Revenue	9.6 billion yen (FY2022)
Launch	June 2020
Indications	Schizophrenia and bipolar depression
Features	An affinity for dopamine D <sub>2</sub> , serotonin 5-HT <sub>2A</sub> and serotonin 5-HT <sub>7</sub> receptors where it has antagonist effects



##### TWYMEEG®

Revenue	2.2 billion yen (FY2022)
Launch	September 2021
Indications	Type 2 diabetes
Features	An oral hypoglycemic agent in a new class with a structure different from other such existing agents



#### Regional Strategy in the Mid-term Business Plan 2027 (Japan)

- Focus on maximizing the value of priority products and new products to ensure business revenue
- Strengthen the Regenerative Medicine/Cell Therapy Business and Frontier Business



# Business Units

## North America Business

Sumitomo Pharma America, Inc., which was integrated in July 2023 through the combination of the group companies conducts research and development, manufacturing, and sales of ethical pharmaceuticals.

### Number of employees

Sumitomo Pharma America, Inc.: Approximately 2,200  
(As of March 31, 2023, include employees of consolidated subsidiaries)

### Main Products

#### ORGOVYX®

Revenue	24.7 billion yen (182 million dollar) (FY2022)
Launch	January 2021
Indications	Prostate cancer
Features	Once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist

#### MYFEMBREE®

Revenue	4.5 billion yen (33 million dollar) (FY2022)
Launch	June 2021
Indications	Uterine fibroids, endometriosis
Features	Once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist

#### GEMTESA®

Revenue	24.7 billion yen (182 million dollar) (FY2022)
Launch	April 2021
Indications	Overactive bladder
Features	Once-daily, oral $\beta_3$ adrenergic receptor agonist effective for all three major symptoms (urge urinary incontinence, urgency, and urinary frequency)



### Regional Strategy in the Mid-term Business Plan 2027 (North America)

- Focus on maximizing the value of the three key products early
- Steadily promote the combination of the group companies in the U.S. and realize synergies



# Business Units

## China Business

Sumitomo Pharma (Suzhou) Co., Ltd. is engaged in manufacturing (subdivided packaging) and sales of pharmaceuticals.

In addition to the Psychiatry & Neurology area, we operate our business with a therapeutic agent for bacterial infections as our main product.

### Number of employees

Sumitomo Pharma (Suzhou) Co., Ltd.: 638 (As of March 31, 2023)

### Main products

#### MEROPEN® (brand name in China: MEPEN®)

Revenue	28.5 billion yen (FY2022)
Indications	General infections, febrile neutropenia
Features	Standard therapy for severe infections, used in many countries



### Regional Strategy in the Mid-term Business Plan 2027 (China and Asia)

Expand the product line while maximizing revenue and profit by launching products in more countries/regions

## Other Regions

### East Asia and South East Asia

Reinforce business functions in Singapore subsidiary and established Thailand, Taiwan, and Malaysia subsidiary

### Europe and others

Collaboration with partners

## Aiming Future

We formulated our new vision, “For Longer and Healthier Lives: We unlock the future with cutting-edge technology and ideas,” to become a company with ability to meet increasingly diversified needs for healthcare in April 2019. With a focus on the Psychiatry & Neurology and Oncology as priority disease areas, Sumitomo Pharma Group will contribute to the betterment of healthcare and fuller lives of people worldwide through diverse approaches, including pharmaceutical products, regenerative medicine/cell therapy, and nonpharmaceutical solutions. In other areas, too, the Group will leverage its assets to deliver value to patients. With this, the Group aims to establish itself as a Global Specialized Player by 2033.

### A Global Specialized Player as Envisioned by Sumitomo Pharma

Psychiatry & Neurology and Oncology as Priority Disease Areas, contribute to the betterment of healthcare and fuller lives of people worldwide through diverse approaches (pharmaceutical products, regenerative medicine/cell therapy, and non-pharmaceutical solutions), thus establishing a unique position globally

